Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03198026 · ClinicalTrials.gov registry record · Phase 2
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
A Phase 2 study of Non-Hodgkin's Lymphoma and Ann Arbor Stage II Follicular Lymphoma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03198026 is a Phase 2 study of Non-Hodgkin's Lymphoma and Ann Arbor Stage II Follicular Lymphoma that is active but no longer recruiting, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 30 participants, below the 221-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03198026, a Phase 2 study of Non-Hodgkin's Lymphoma and Ann Arbor Stage II Follicular Lymphoma, is active but no longer recruiting, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well obinutuzumab and ibrutinib work as front line therapy in treating patients with indolent non-Hodgkin's lymphoma. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving obinutuzumab and ibrutinib may work better in treating patients with non-Hodgkin's lymphomas.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Obinutuzumab
- DRUG Ibrutinib
Study Locations (1)
Pennsylvania
- Sidney Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-02-20 |
| Est. Completion | 2032-02-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03198026
The ClinicalTrials.gov registry entry for NCT03198026 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (86% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03198026 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03198026 about?
NCT03198026 is a clinical study titled "Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas". This phase II trial studies how well obinutuzumab and ibrutinib work as front line therapy in treating patients with indolent non-Hodgkin's lymphoma. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Ibrutinib may stop the growth of cance...
What is the current status of trial NCT03198026?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2018-02-20. Estimated completion is 2032-02-20.
What conditions does trial NCT03198026 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue.
What interventions are being tested in trial NCT03198026?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Obinutuzumab (BIOLOGICAL), Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT03198026?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03198026 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cord Blood Transplant in Adults With Blood Cancers
RECRUITING · Phase 2
-
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
RECRUITING · Phase 2
-
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
RECRUITING · Phase 2
-
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
RECRUITING · Phase 2
-
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Non-Hodgkin's Lymphoma
All registered trials for this condition
Ann Arbor Stage II Follicular Lymphoma
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.